MorphoSys AG

SWX:MOR Stock Report

Market Cap: CHF 2.4b

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

MorphoSys Valuation

Is MOR undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of MOR when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate MOR's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate MOR's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for MOR?

Other financial metrics that can be useful for relative valuation.

MOR key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue17.1x
Enterprise Value/EBITDA-9.3x
PEG Ration/a

Price to Sales Ratio vs Peers

How does MOR's PS Ratio compare to its peers?

The above table shows the PS ratio for MOR vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average11.7x
BSLN Basilea Pharmaceutica
3.6x9.2%CHF 543.6m
KURN Kuros Biosciences
17.3xn/aCHF 908.3m
IDIA Idorsia
1.7x39.9%CHF 214.0m
MOLN Molecular Partners
24.2x53.2%CHF 190.5m
MOR MorphoSys
10.5x25.0%CHF 2.5b

Price-To-Sales vs Peers: MOR is good value based on its Price-To-Sales Ratio (10.5x) compared to the peer average (11.1x).

Price to Earnings Ratio vs Industry

How does MOR's PE Ratio compare vs other companies in the European Biotechs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a35.7%
 n/an/an/a
No. of CompaniesPS048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a35.7%
 n/an/an/a
No more companies

Price-To-Sales vs Industry: MOR is expensive based on its Price-To-Sales Ratio (10.5x) compared to the European Biotechs industry average (9.5x).

Price to Sales Ratio vs Fair Ratio

What is MOR's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

MOR PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio10.5x
Fair PS Ratio7.5x

Price-To-Sales vs Fair Ratio: MOR is expensive based on its Price-To-Sales Ratio (10.5x) compared to the estimated Fair Price-To-Sales Ratio (7.5x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst MOR forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCHF 102.00
CHF 59.21
-42.0%
16.5%CHF 63.57CHF 37.39n/a6
Oct ’25n/a
CHF 59.21
0%
16.5%CHF 63.57CHF 37.39n/a6
Sep ’25n/a
CHF 59.21
0%
16.5%CHF 63.57CHF 37.39n/a6
Aug ’25CHF 102.00
CHF 55.35
-45.7%
25.3%CHF 64.11CHF 29.22n/a7
Jul ’25CHF 102.00
CHF 57.61
-43.5%
25.3%CHF 66.73CHF 30.42n/a7
Jun ’25CHF 102.00
CHF 57.61
-43.5%
25.3%CHF 66.73CHF 30.42n/a7
May ’25CHF 102.00
CHF 57.61
-43.5%
25.3%CHF 66.73CHF 30.42n/a7
Apr ’25CHF 102.00
CHF 56.48
-44.6%
25.3%CHF 65.42CHF 29.82n/a7
Mar ’25CHF 102.00
CHF 47.43
-53.5%
36.4%CHF 64.03CHF 20.71n/a8
Feb ’25CHF 102.00
CHF 29.29
-71.3%
33.5%CHF 43.91CHF 14.01n/a10
Jan ’25CHF 102.00
CHF 29.21
-71.4%
33.6%CHF 44.28CHF 14.13n/a10
Dec ’24CHF 102.00
CHF 30.03
-70.6%
33.3%CHF 45.34CHF 14.47n/a8
Nov ’24CHF 102.00
CHF 33.05
-67.6%
17.8%CHF 43.32CHF 24.07n/a9
Oct ’24CHF 102.00
CHF 30.14
-70.5%
29.1%CHF 42.90CHF 12.87n/a9
Sep ’24CHF 102.00
CHF 26.81
-73.7%
38.9%CHF 43.18CHF 11.99n/a8
Aug ’24CHF 102.00
CHF 26.89
-73.6%
40.0%CHF 44.84CHF 11.93CHF 102.008
Jul ’24CHF 102.00
CHF 25.02
-75.5%
50.9%CHF 46.00CHF 12.23CHF 102.008
Jun ’24CHF 102.00
CHF 22.45
-78.0%
59.3%CHF 45.75CHF 11.68CHF 102.008
May ’24CHF 102.00
CHF 17.99
-82.4%
58.8%CHF 41.25CHF 10.80CHF 102.008
Apr ’24CHF 102.00
CHF 18.09
-82.3%
58.8%CHF 41.49CHF 10.87CHF 102.008
Mar ’24CHF 102.00
CHF 18.02
-82.3%
59.2%CHF 41.48CHF 10.86CHF 102.008
Feb ’24CHF 102.00
CHF 23.15
-77.3%
76.2%CHF 64.18CHF 10.86CHF 102.009
Jan ’24CHF 102.00
CHF 24.72
-75.8%
67.8%CHF 64.14CHF 11.84CHF 102.009
Dec ’23CHF 102.00
CHF 28.58
-72.0%
60.9%CHF 63.82CHF 12.76CHF 102.009
Nov ’23CHF 102.00
CHF 35.05
-65.6%
39.6%CHF 63.98CHF 17.72CHF 102.009
Oct ’23CHF 102.00
CHF 35.94
-64.8%
34.1%CHF 62.85CHF 23.20CHF 102.009

Analyst Forecast: Target price is lower than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y